A lot of research is being done in immunotherapy for myeloma that is leading to new treatment options for patients. Dr. Ivan Borrello of John Hopkins is working on a completely, novel approach. This involves enhancing white blood cells to create a customized immunotherapy for patients. The T-cells from the patient's bone marrow are extracted, enhanced, and expanded in the lab, and are given back to the patient, allowing for a more specific immune response targeting the proteins found on their myeloma cells. The use of bone marrow T cells is more precise than the use of cells from the blood which makes this therapy more effective. Join our myeloma panel talk on this new area of research, as they discuss the difference between CAR-T cells and MILs (marrow infilterating lymphocytes), and how body's natural immune cell growth can be used to fight myeloma.
Sorry we couldn't complete your registration. Please try again.
You must accept the Terms and conditions to register